ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0205

Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, Psoriatic arthritis, rheumatoid arthritis, socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Health Services Research – ACR/ARP Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: A growing body of evidence highlights a link between rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) and an increased risk of cardiovascular events (CVE). Investigating this relationship and the specific risk factors associated with CVE in this population is vital for early identification, prevention and risk stratification. The objective of this study was to identify risk factors for CVE in RA, SLE, and PSA members.

Methods: This was a cohort study of commercial fully-insured and Medicare Advantage members of a large national health plan between 1/1/2018 and 1/1/2024. Members ≥ 18 years old were included if they had at least 2 claims for RA (ICD-10 code: M05 or M06), PSA (L40.5), or SLE (M32) during the evaluation period; members with a prior MI or ischemic stroke were included. Members were excluded if they did not maintain continuous eligibility for 6 months before or after entrance into the analysis, had multiple conditions of interest (RA, PSA, or SLE), or had missing socioeconomic status (SES) data. The primary outcome was incidence of CVE defined by ICD-10 codes for myocardial infarction (MI; I21.X, I22.X, I23.X) or ischemic stroke (I63.X, I64.X). Member demographics, social determinants of health (SDoH), and comorbidities were analyzed for those with CVE and those without. Continuous variables were assessed with an independent t-test or Mann-Whitney U test; categorical variables were assessed with a ꭓ2 test. Bivariate and multivariate Poisson regression was utilized to identify correlations between variables and CVE rates; p-values < 0.05 were significant.

Results: 70,690 members were included with 4,176 (5.9%) experiencing a CVE during the evaluation period or 30.9 cases per 1,000 person-years (PY) observed. Among the conditions of interest, PSA had lower incidence rates than RA and SLE (18.8 [16.6-21.2] cases/1,000 PY vs. 32.6 [31.5-33.7] and 30.7 [20.1-33.5] cases/1,000 PY, respectively; p< 0.001 for both comparisons). Members experiencing CVE were older, (66+ years of age) more likely to be male, have Medicare insurance, have lower SES, and with more comorbidities (Table 1). CVE incidence risk increased with age, with lowest risk being in members aged 18-45 years and highest being in members aged >75 years (Figure 1). Comorbidities associated with increased CVE risk include history of MI, congestive heart failure, dementia, peripheral vascular disease, renal disease, AIDS, diabetes mellitus, metastatic cancer, depression, liver disease, ulcers, and congestive obstructive pulmonary disease (Figure 2). SDoH factors were not associated with CVE risk in the final multivariate model.

Conclusion: In this evaluation of a population of members with elevated CVE risk, factors associated with CVE appear to parallel those seen in other high-risk populations, namely increasing age, and chronic comorbidities. SDoH factors were not associated with CVE incidence; however, additional investigation is warranted.

Supporting image 1

Table 1. Sociodemographic and clinical characteristics of members with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus (N=70,690)

Supporting image 2

Figure 1. Forest plot of variables associated with cardiovascular event in members with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus

Supporting image 3

Figure 2. Forest plot of comorbidities associated with cardiovascular events in members with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus


Disclosures: J. Park: CVS Health, 3, 11; C. Rutter: CVS Health, 3, 11; E. Avalos-Reyes: AstraZeneca, 11, CVS Health, 3, 11, GlaxoSmithKlein(GSK), 11, Haleon, 11, Johnson & Johnson, 11, Moderna, 11, Novavax, 11, Pfizer, 11, Viatris, 11; M. Anderson: CVS Health, 3, 11; W. Cavers: CVS Health, 3, 11; D. Verbrugge: CVS Health, 3, 4, 11; K. Johnson: CVS Health, 3, 4, 11.

To cite this abstract in AMA style:

Park J, Rutter C, Avalos-Reyes E, Anderson M, Cavers W, Verbrugge D, Johnson K. Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-event-risks-among-members-with-rheumatoid-arthritis-psoriatic-arthritis-and-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-event-risks-among-members-with-rheumatoid-arthritis-psoriatic-arthritis-and-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology